Incidence of benign prostate hypertrophy in Danish men with and without HIV infection

Ahlström, Magnus Glindvad; Kronborg, Gitte; Larsen, Carsten Schade; Pedersen, Court; Pedersen, Gert Frølund; Gerstoft, Jan; Obel, Niels

doi:10.1097/qad.0000000000000804

Cited by 2 publications

(1 citation statement)

References 36 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One such group who may benefit from a medication review are males living with HIV who have developed lower urinary tract symptoms (LUTS) in relation to benign prostatic hyperplasia [6]. Drugs to treat LUTS are known for both their potential role as victims in DDIs and their side effects (e.g., hypotension, dizziness, abnormal ejaculation) [7].…”

Section: Introductionmentioning

confidence: 99%

Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms

Burger,

Oosterhof,

Grintjes

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

ObjectiveLower urinary tract symptoms (LUTS) are becoming more prevalent in the ageing population of males living with HIV. Drugs to treat LUTS are known for both their potential role as victims in drug–drug interactions (DDIs) and their side effects. We aimed to evaluate the current use of drugs to treat LUTS and to assess potential DDIs in our cohort of adult males living with HIV.DesignThis was a retrospective review of pharmacy records.MethodsWe recorded the combination antiretroviral therapy (cART) regimen and any use of drugs to treat LUTS (anatomical therapeutic chemical codes G04CA/CB/CX and G04BD). Potential DDIs were assessed using the interaction checker developed by the University of Liverpool (https://www.hiv-druginteractions.org/checker).ResultsA total of 411 adult males living with HIV were included in this analysis. The median (interquartile range [IQR]) age was 53 (41–62) years. Nineteen (4.6%) patients used one or more drugs to treat LUTS. As expected, older patients were more likely to be receiving treatment for LUTS: Q1 (20–40 years) = 0%; Q2 (41–52 years) = 2%; Q3 (53–61 years) = 7%; Q4 (62–79 years) = 10%. Seven potential DDIs between cART and LUTS treatment were noted in six of the 19 (32%) patients. Following medication reviews of these six patients, the following interventions were proposed: evaluate safe use of alpha‐blocker (n = 4), change in cART (n = 2), and dose reduction of the anticholinergic agent (n = 1).ConclusionTreatment for LUTS coincided with cART in 7%–10% of patients aged above the median age of 53 years in our cohort. Improvements in DDI management appeared to be possible in this growing cohort of males living with HIV and with LUTS.

show abstract

Section: Introductionmentioning

confidence: 99%

Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms

Burger,

Oosterhof,

Grintjes

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

show abstract

Symptoms and quality of life in HIV-infected patients with benign prostatic hyperplasia are improved by the consumption of a newly developed whole tomato-based food supplement. A phase II prospective, randomized double-blinded, placebo-controlled study

Quirós-Roldán

Carriero

Paghera

et al. 2021

Journal of Functional Foods

View full text Add to dashboard Cite

Incidence of benign prostate hypertrophy in Danish men with and without HIV infection

Abstract: HIV-infected individuals do not have an increased risk of being diagnosed with BPH.

Cited by 2 publications

References 36 publications

Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms

Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms

Symptoms and quality of life in HIV-infected patients with benign prostatic hyperplasia are improved by the consumption of a newly developed whole tomato-based food supplement. A phase II prospective, randomized double-blinded, placebo-controlled study

Contact Info

Product

Resources

About